At 10:22 IST, the barometer index, the S&P BSE Sensex, rose 208.77 points or 0.38% at 54,527.24. The Nifty 50 index rose 68.70 points or 0.42% at 16,328.
In the broader market, the S&P BSE Mid-Cap index rose 0.45% while the S&P BSE Small-Cap index rose 0.79%. Both these indices outperformed the Sensex.
The market breadth, indicating the overall market health, was strong. On the BSE, 2116 shares rose and 860 shares fell. A total of 133 shares were unchanged.
Buzzing Index:
The Nifty IT index rose 1.22% to 30,587.35, extending its gaining streak to the second consecutive day. The index has gained 4.02% in two days.
Among the components of the Nifty IT index, Mphasis (up 4.23%), L&T Technology Services (up 3.19%), Mindtree (up 2.62%), Coforge (up 2.38%) and Larsen & Toubro Infotech (up 2.16%) were the top gainers.
Stocks in Spotlight:
Indian Oil Corporation (IOCL) slipped 3.46% to Rs 120.10 after the company reported 31.4% fall in standalone net profit to Rs 6021.88 crore despite a 43.2% increase in net sales to Rs 1,77,287.31 crore in Q4 FY22 over Q4 FY21. Total expenses increased by 29.5% YoY to Rs 1,99,327.91 crore during the quarter. Profit before tax in Q4 FY22 stood at Rs 8,084.68 crore, down by 26.2% from Rs 10,951.10 crore in Q4 FY21.
The IOCL board recommended issue of bonus equity shares in the ratio of 1 equity share for every two equity shares held. The bonus shares will also be eligible for the final dividend of Rs 3.60 per equity share (pre-bonus), which translates into final dividend of Rs 2.40 per equity share (post-bonus) for FY 2021-22.
DLF rose 0.66% to Rs 336.35. The realty major reported 15.7% fall in consolidated net profit to Rs 405.33 crore on a 9.7% decline in net sales to Rs 1,547.26 crore in Q4 FY22 over Q4 FY21. Profit before tax stood at Rs 307.30 crore in the fourth quarter, down by 26.5% from Rs 418.15 crore in the same period last year. The company reported a 6.3% decline in total expenditure to Rs 1,179.72 crore in Q4 FY22 over Q4 FY21.
Zydus Lifesciences fell 0.69% to Rs 346.65. The company said its board will consider a share buyback on 20 May 2022. The board will also consider FY22 results and final dividend on 20 May 2022. Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
